Open AccessSerum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis
Author(s) -
Rennie L. Rhee,
Cécile Holweg,
Kit Wong,
David Cuthbertson,
Simon Carette,
Nader Khalidi,
Curry L. Koening,
Carol A. Langford,
Carol A. McAlear,
Paul A. Monach,
Larry W. Moreland,
Christian Pagnoux,
Philip Seo,
Ulrich Specks,
Antoine G. Sreih,
Steven R. Ytterberg,
Peter A. Merkel
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0205768
Subject(s) - periostin , granulomatosis with polyangiitis , medicine , asthma , biomarker , eosinophilic , prospective cohort study , cohort , gastroenterology , disease , vasculitis , pathology , biochemistry , chemistry , extracellular matrix , biology , microbiology and biotechnology
Objective Identification of a biomarker for disease activity in eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss) remains an unmet need. This study examined the value of serum periostin, a marker of type 2 inflammation, as a measure of disease activity in patients with EGPA. Methods Participants enrolled in a multicenter, prospective cohort of patients with EGPA were included in this study if they had disease activity (defined as Birmingham Vasculitis Activity Score [BVAS] > 0) during follow-up. Serum levels of periostin were measured at flare visit as well as two pre- and two post-flare visits, if available. The outcome of disease activity was assessed either with BVAS or Physician Global Assessment (PGA). Mixed-effect models were used to examine the association between periostin levels and disease activity. Comparisons were made with a historical cohort of healthy individuals and patients with asthma. Results In the 49 patients included in the study, the median periostin level was 60 ng/ml (IQR 50 to 73) in all visits and did not significantly change across visits. Multivariate analyses found no association between periostin level and presence or absence of flare according to the BVAS (adjusted OR 1.00 [95% CI 0.98 to 1.02], p = 0.98) but an increase in periostin level was significantly associated with greater disease severity during a flare according to the PGA (adjusted beta-coefficient 0.02 [95% CI 0.004 to 0.03], p = 0.01). Periostin levels in EGPA were significantly higher than previously studied healthy controls and patients with asthma. Conclusion In EGPA serum periostin level is modestly associated with greater disease severity during a flare but does not discriminate active from inactive disease. Periostin levels in EGPA are higher than in other previously studied cohorts, including healthy populations and patients with asthma, and are relatively stable over time.